Altered vessel signalling molecules in subjects with Down's syndrome

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 1, 2006, Pages 181-185

  Licastro, F ^a,e   Chiappelli, M ^a   Porcellini, E ^a   Trabucchi, M ^b   Marocchi, A ^c   Corsi, M M ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b GERIATRIC RESEARCH GROUP   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Dipartimento di Patologia Sperimentale   (Italy)

Author keywords

Down's syndrome; Monocyte chemoattractant protein 1; Vascular endothelial growth factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; GROUPS BY AGE; HUMAN; INFLAMMATION; MALE; MORPHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 33646230775     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/205873920601900118     Document Type: Article

References (33)

1. Sever J.L., M.R. Gilkeson, T.C. Chen, A.C. Ley and D. Edmonds. 1970. Epidemiology of mongolism in the Collaborative Project. Ann. N.Y. Acad. Sci. 171:328.
2. Baird P.A. and A.D. Sadovnick. 1988. Causes of death to age 30 in Down syndrome. Am. J. Hum. Genet. 43:239.
3. Franceschi C., F. Licastro, M. Chiricolo, F. Bonetti, M. Zannotti, N. Fabris, E. Mocchegiani, M.P. Fantini, P. Paolucci and M. Masi. 1981. Deficiency of autologous mixed lymphocyte reactions and thymic factor level in Down's syndrome. J. Immunol. 126:216.
4. Wisniewski K., H.M. Wisniewski and G.Y. Wen. 1985. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:278.
5. Mann D.M. and M.M. Esiri. 1989. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 89:169.
6. Licastro F., R.A. Mariani, G. Faldella, E. Carpenè, G. Guidicini, A. Rangoni, T. Grilli and G. Bazzocchi. 2001. Immune-endocrine status and coeliac disease in children with Down's syndrome: Relationships with zinc and cognitive efficiency. Brain Res. Bull. 55:313.
7. Carta M.G., P. Serra, A. Ghiani, E. Manca, M.C. Hardoy, G.S. Del Giacco, G. Diaz, B. Carpiniello and P.E. Manconi. 2002. Chemokines and proinflammatory cytokines in Down's Syndrome: An early marker for Alzheimer-type dementia? Psychother. Psychosom. 71:233.
8. Licastro F, M. Chiappelli, M. Ruscica, V. Carnelli and M.M. Corsi. 2005. Altered cytokine and acute phase response protein levels in the blood of children with Down's syndrome: relationship with dementia of Alzheimer's type. Int. J. Immunopathol. Pharmacol. 18:165.
9. Gosling J., S. Slaymaker, L. Gu, S. Tseng, C.H. Zlot, S.G. Young, B.J. Rollins and I.F. Charo. 1999. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103:773.
10. Weber K.S., P.J. Nelson, H.J. Grone and C. Weber. 1999. Expression of CCR2 by endothelial cells: implication for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium. Arterioscler. Throm. Vasc. Biol. 19:2085.
11. Salcedo R., M.L. Ponce, H.A. Young, K. Wasserman, J.M. Ward, H.K. Kleinman, J.J. Oppenheim and W.J. Murphy. 2000. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34.
12. van Royen N., I. Hoefer, M. Bottinger, J. Hua, S. Grundmann, M. Voskuil, C. Bode, W. Schaper, I. Buschmann and J.J. Piek. 2003. Local monocyte chemoactrant protein -1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocyte CD11b expression, neointimal formation, and plaque progression. Circ. Res. 92:218.
13. Hong K.H., J. Ryu and K.H. Han. 2005. Monocyte chemoattractant-1 induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105:1405.
14. Ferrara N. and H.P. Gerber. 2001. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 106:148.
15. Fuentes J.J., M.A. Pritchard, A.M. Planas, A. Bosh, I. Ferrer and X. Estiville. 1995. A new human gene from the Down syndrome critical region encodes a praline-rich protein highly expressed in fetal brain and heart. Hum. Mol. Genet. 4:1935.
16. Rothermel B., R.B. Vega, J. Yang, H. Wu, R. Bassel-Duby and R.S. Williams. 2000. A protein encoded within the Down syndrome critical region is enriched in striated muscle and inhibits calcineurin signaling. J. Biol. Chem. 275:8719.
17. Hesser B.A., X.H. Liang, G. Camenisch, S. Yang, D.A. Lewin, R. Scheller, N. Ferrara and H.P. Gerber. 2004. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 104:149.
18. Kalehua A.N, J.E. Nagel, L.M. Whelchel, J.J. Gides, R.S. Pyle, R.J. Smith, Kusiak and D.D. Taub. 2004. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp. Cell. Res. 297:197.
19. Hughes P.M, P.R Allegrini, M. Rudin, V.H Perry, A.K. Mir and C. Wiessner. 2002. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model J. Cereb. Blood Flow Metab. 22:308.
20. Grammas P. and R. Ovase. 2001 Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging 22:837.
21. Yamamoto M., M. Horiba, J.L. Buescher, D. Huang, H.E. Gendelman, R.M. Ransohoff and T. Ikezu. 2005. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am. J. Pathol. 166:1475.
22. Storkebaum E. and P. Carmeliet. 2004. VEGF: a critical player in neurodegeneration. J. Clin. Invest. 113:14.
23. Del Bo R., M. Scarlato, S. Ghezzi, F. Martinelli Boneschi, C Fenoglio, S Galbiati, R. Virgilio, D. Galimberti, G. Galimberti, M. Crimi, C. Ferrarese, E. Scarpini, N. Bresolin and G.P. Comi. 2005. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann. Neurol. 57:373.
24. Licastro F., L.M. Grimaldi, M. Bonafe, C. Martina, F. Olivieri, L. Cavallone, S. Giovanietti, E. Masliah and C. Franceschi. 2003. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol. Aging 24:921.
25. Ershler W.B. and E.T. Keller. 2000. Age-associated increased interleukin-6 gene expression, late-life diseases and frailty. Annu. Rev. Med. 51:245.
26. Licastro F., S. Pedrini, L. Caputo, G. Annoni, L.J. Davis, C. Ferri, V. Casadei and L.M.E. Grimaldi. 2000. Increased plasma levels of interlukin-1, interleukin-6 and aplha-1 antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signal from the brain. J. Neuroimmunol. 103:97.
27. Angelis P., S. Scharf, A. Mander, F. Vajda and N. Christofhidis. 1998. Serum interleukin-6 soluble receptor in Alzheimer's disease. Neurosci. Lett. 244:106.
28. Weaver J.D., M.H. Huang, M. Albert, T. Harris, J.W. Rowe and T.E. Seeman. 2002. Interleukin-6 and the risk of cognitive decline. MacArthur Studies of Successful Aging. Neurology 59:371.
29. Theoharides T.C., C. Weinkauf and P. Conti. 2004. Brain cytokines and neuropsychiatric disorders. J. Clin. Psychopharmacol. 24:577.
30. Ridker P.M., N. Rifai, M.J. Stampfer and C.H. Hennekens. 2000. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767.
31. Hopkins W.E., N.K. Fukagawa, B.E. Sobel and D.J. Schneider. 2000. Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease. Am. J. Cardiol. 85:784.
32. Yla-Herttuala S., J. Luoma, T. Nikkari and T. Kivimaki. 1989. Down's syndrome and atherosclerosis. Atherosclerosis 76:269.
33. Murdoch J.C., J.C. Rodger, S.S. Rau, C.D. Fletcher and M.G. Dunnigan. 1977. Down's syndrome: an atheroma free model? Br. Med. J. 23:226.